eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2003
vol. 28
 
Share:
Share:
abstract:

Review paper

The lectin pathway of complement activation. The role of complement in pathological processes and possible strategies of its activity modulation in therapy of some diseases

Anna Świerzko
,
Kazimierz Madaliński
,
Maciej Cedzyński

(Centr Eur J Immunol 2003; 28(2): 67–73)
Online publish date: 2004/01/20
View full text Get citation
 
Abstract

Complement activation pathways with particular attention to lectin pathway were reminded. The current trend is that detailed knowledge of activation triggers and substrates may pave the way to clinical interventions, i.e. inhibition of undesirable excessive activation of complement. Cellular receptors, possible inhibitors of complement cascade, and a list of diseases in which inhibition of complement is needed were shown. C1-inhibitor has its established value in the treatment of hereditary angioedema, but several other inhibitors, like soluble complement receptors, anti-C3 (-C3a), anti-C5 (-C5a) are proposed as therapeutic agents. These inhibitors may be useful in decreasing tissue lesions in such dangerous diseases as eg. Ischemic stroke, myocardial infarct, and septicemia (septic shock).Recently, also mannan binding lectins may be used in therapeutic interventions.
keywords:

lectin pathway of complement, disease consequences of of complement activation, complement inhibitors

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.